FDA Approves Nirsevimab Antibody Injection To Protect Babies And Toddlers From RSV

The AP (7/17, Perrone) reports that the FDA approved nirsevimab injection, developed by Sanofi and AstraZeneca, “for infants and children up to 2 years old who face increased risk of severe RSV.” The drug “is a laboratory-made version of an antibody that...